Alvotech Swiss AG
Quick facts
Marketed products
- Simponi · Oncology
Phase 3 pipeline
- Adalimumab biosimilar · Immunology
Adalimumab biosimilar is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling. - Adalimumab originator · Immunology
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling. - AVT03 · Immunology / Rheumatology
AVT03 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation. - AVT04 · Oncology
AVT04 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. - Eylea® (Aflibercept) · Ophthalmology
Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye. - Eylea HD (aflibercept HD) · Ophthalmology
Eylea HD is a high-dose formulation of aflibercept, a VEGF trap that binds and inhibits vascular endothelial growth factor to reduce abnormal blood vessel growth and leakage in the eye. - Simponi (Golimumab) · Immunology
Simponi (Golimumab) is a monoclonal antibody that selectively binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Alvotech Swiss AG
What are Alvotech Swiss AG's marketed drugs?
Top marketed products include Simponi.
What is Alvotech Swiss AG's pipeline?
Alvotech Swiss AG has 7 drugs in Phase 3, 0 in Phase 2, 6 in Phase 1. Late-stage candidates include Adalimumab biosimilar, Adalimumab originator, AVT03, AVT04.
Related
- Simponi · Oncology
- Sector hub: All tracked pharma companies